Skip to main content

Table 3 Utilities and utility decrements used in modelling studies

From: Health economic evaluations comparing insulin glargine with NPH insulin in patients with type 1 diabetes: a systematic review

Author/Study

Cameron et al.

[21]

Grima et al.

[22]

McEwan et al.

[23]

Brändle et al.

[25]

Warren et al.

[24]

Warren et al.

[20]

Health state

Utility decrement a

Utility values f

Utility decrement a

Utility decrement a

Utility decrement a

Data except for hypoglycaemia confidential to NICE

Ischaemic heart disease, first & subsequent years

-

-

-0.09

-0.09

n/a

n/a

Myocardial infarction, year of event

-0.0409222

0.760

-0.066

-0.055

n/a

n/a

Myocardial infarction, subsequent years

-0.012

0.800

-0.066

-0.055

n/a

n/a

Angina, year of event

-0.0411989

-

-

-

n/a

n/a

Angina, subsequent years

-0.024

-

-

-

n/a

n/a

Congestive heart failure, year of event

-0.0546

0.693

-0.108

-0.108

n/a

n/a

Congestive heart failure, subsequent years

-0.018

0.693

-0.108

-0.108

n/a

n/a

Stroke, year of event

-0.0523513

0.720

-0.114

-0.164

n/a

n/a

Stroke, subsequent years

-0.040

0.800

-0.114

-0.164

n/a

n/a

Peripheral vascular disease

-0.021

-

-

-

n/a

n/a

Microalbuminuria

-0.012

-

-

-

n/a

n/a

Proteinuria

-0.017

-

-

-

n/a

n/a

ESRD, first and subsequent years

-

0.644

-0.263

-0.263

n/a

n/a

Dialysis, first & subsequent years

-0.16

-

-0.305

-0.305

n/a

n/a

Funct. kidney transplant, first & subsequent years

-0.03

-

-0.075

-0.075

n/a

n/a

Diabetic retinopathy

-0.0155836

0.750

-

-

n/a

n/a

Blindness and low vision

-0.0497859

-

-

-

n/a

n/a

Pre-blind, first & subsequent years

-

-

-0.029

-0.029

n/a

n/a

Blind, first & subsequent years

-

-

-0.074

-0.074

n/a

n/a

Cataract

-0.0170832

-

-

-

n/a

n/a

Macular edema

-0.0170832

-

-

-

n/a

n/a

Neuropathy

-0.0243702

-

-

-

n/a

n/a

Active uninfected diabetic ulcer

-0.09

-

-

-

n/a

n/a

Active infected diabetic ulcer

-0.14

-

-

-

n/a

n/a

Amputation

-0.266

0.678

-0.28

-0.28

n/a

n/a

Amputation, subsequent years

-

0.800

-

-

n/a

n/a

Fear of any hypoglycaemic episode

-

-

-

-

-0.0019d

-0.0052d

Severe hypoglycaemic episode

-0.5485b

-

-0.047d

-0.047d

-0.15e

-0.15e

Mild/moderate hypoglycaemic episode

-0.167c

-

-

-

-

-

Symptomatic hypoglycaemic episode

-

-

-0.0142d

-0.0142d

-

-

Nocturnal hypoglycaemic episode

-

-

-0.0084d

-0.0084d

-

-

  1. Legend: ESRD = endstage renal disease
  2. aapplied for 1-year (but not for subsequent years, hypoglycemic episodes and ulcers)
  3. bdecrement for 24 hours
  4. cdecrement for 15 minutes
  5. dunclear duration
  6. edecrement for 4 days
  7. fnot additive, lowest utility in respective year is used
Back to article page

Cost Effectiveness and Resource Allocation

ISSN: 1478-7547

Contact us